<DOC>
	<DOC>NCT01544140</DOC>
	<brief_summary>The purpose of this study in healthy volunteers is to assess the Pharmacokinetics (PK) of Midazolam administered alone and in combination with Vandetanib.</brief_summary>
	<brief_title>Study in Healthy Volunteers to Assess the Pharmacokinetics of Midazolam Administered Alone and in Combination With Vandetanib</brief_title>
	<detailed_description>A Phase I, Open-label, Single-center Study to Assess the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, in Healthy Subjects When Administered Alone and in Combination with a Single Dose of 800-mg Vandetanib (CAPRELSA)</detailed_description>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Provision of signed and dated, written informed consent prior to any study specific procedures: Volunteers must be males or females aged 18 to 50 years and with a weight of at least 50 kg and body mass index (BMI) between 18 and 30 kg/m2, inclusive Females must have a negative pregnancy test at screening and on admission to the study center. Females must not be lactating and must be of nonchildbearing potential defined as postmenopausal or documentation of irreversible surgical sterilization. History of any clinically significant disease or disorder such as gastrointestinal, hepatic, renal or skin disease. History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, Volunteers who smoke more than 5 cigarettes per day or are unable to refrain from smoking while resident in the study center Screening blood pressure of greater than 140/90 mmHg and/or a resting heart rate of less than 45 beats per minute (repeat test allowed at the Investigator's discretion) Clinically significant abnormal12lead ECG as assessed by the Investigator, QTcF interval greater than 450 ms Any positive result on screening for: serum hepatitis B surface antigen, hepatitis C antibody, and human immunodeficiency virus (HIV), or Positive screen for drugs of abuse.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>healthy volunteers</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>vandetanib</keyword>
	<keyword>midazolam</keyword>
</DOC>